Tirzepatide Once Weekly for Obesity: Results from the SURMOUNT-1 Trial

This was the SURMOUNT-1 trial — a phase 3, double-blind, randomized, placebo-controlled study. A total of 2,539 adults with a BMI of 30 or higher (or 27+ with at least one weight-related complication), excluding those with diabetes, were randomly assigned 1:1:1:1 to receive subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, once weekly for 72 weeks. Doses were gradually escalated over the first 20 weeks. The two primary endpoints were percentage change in body weight and the proportion achieving at least 5% weight loss.

This trial established tirzepatide as one of the most effective anti-obesity medications ever tested, producing weight loss approaching what was previously only seen with surgery. As the pivotal trial supporting Zepbound's FDA approval for obesity, SURMOUNT-1 reshaped expectations for what pharmacotherapy can achieve in weight management and opened the door for a new class of dual-agonist peptide drugs.

SURMOUNT-1 was a landmark moment for obesity pharmacotherapy. Before tirzepatide, the most effective approved weight-loss drug (semaglutide 2.4 mg) produced about 15% weight loss. Tirzepatide's dual GIP/GLP-1 mechanism pushed that ceiling to over 20%, entering territory once reserved for bariatric surgery. This trial helped establish the principle that targeting multiple incretin pathways simultaneously can amplify metabolic benefits, influencing the entire pipeline of next-generation obesity drugs.

The trial excluded people with diabetes, so results may not directly apply to that population (separate trials addressed this). The 72-week duration, while substantial, does not answer questions about weight maintenance after stopping the drug. The study population was predominantly female and had a mean BMI of 38, so results may vary in other demographics. Gastrointestinal side effects led to discontinuation in up to 7.1% of participants at the 10 mg dose.